Provision of reagents for GridION platforms to support COG-UK

A Contract Award Notice
by PUBLIC HEALTH ENGLAND

Source: Find a Tender
Type: Contract (Goods)
Duration: not specified
Value: £264K

Sector: HEALTH
Published: 07 Apr 2021
Delivery: not specified
Deadline: n/a

Concepts

Location

United Kingdom:

Geochart for 1 buyers and 1 suppliers

1 buyer

Public Health England Salisbury

1 supplier

New England Biolabs Hertfordshire

Description

Public Health England (PHE) has awarded a contract to New England Biolabs UK Ltd for the provision of reagents to be used on GridION platforms urgently needed to support the COVID-19 Genomics UK (COG-UK) consortium work. PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak.

Total Quantity or Scope

This single tender action request is for the purpose of procuring reagents to be used on GridION platforms needed to support the COVID-19 Genomics UK (COG-UK) consortium work.

Award Detail

1	New England Biolabs (Hertfordshire) Reference: 007163-2021-1 Value: £264,000

Award Criteria

price

CPV Codes

33696300 - Chemical reagents

Legal Justification

The UK Government must protect the health and wellbeing of UK citizens. The COVID-19 outbreak is a Public Health Emergency of International Concern (PHEIC) as declared by the World Health Organisation on 30 January 2020. The WHO Director General characterised COVID-19 as a pandemic on 11 March 2020. PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health and Social Care within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak. The negotiated procedure without a prior publication has been used due to extreme urgency on the grounds of regulation 32(2)(c). This requirement is provided at short notice to support reduced testing turnaround times which are critical in the current outbreak and increased coronavirus testing capacity using an approved assay.